Brought to you by 
Celgene and Array sign second option deal, Array gets $11mm to start
07 Dec 2015
Executive Summary
Celgene Corp. and Array BioPharma Inc. (therapies for cancer and inflammatory diseases) have teamed up again, in their second collaboration since 2007. This time, Celgene gets an exclusive option to license some of Array’s preclinical projects targeting an undisclosed inflammatory pathway.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene and Array sign second option deal, Array gets $11mm to start
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice